Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
307 studies found for:    "Vasculitis"
Show Display Options
Rank Status Study
1 Recruiting Vasculitis Pregnancy Registry
Conditions: Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis With Polyangiitis (EGPA);   Churg-Strauss Syndrome (CSS);   Granulomatosis With Polyangiitis (GPA);   Wegener's Granulomatosis;   IgA Vasculitis;   Henoch-Schoenlein Purpura (HSP);   Microscopic Polyangiitis (MPA);   Polyarteritis Nodosa (PAN);   Takayasu Arteritis (TAK);   Urticarial Vasculitis;   Systemic Vasculitis
Intervention: Other: Online questionnaires
2 Recruiting Pediatric Vasculitis Initiative
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis);   Microscopic Polyangiitis;   Churg Strauss Syndrome (Eosinophilic Granulomatosis With Polyangiitis);   Polyarteritis Nodosa;   Takayasu Arteritis;   Primary CNS Vasculitis;   Unclassified Vasculitis
Intervention:
3 Completed Impact of Vasculitis on Employment and Income
Conditions: Vasculitis;   Systemic Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis;   Temporal Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa (PAN);   Takayasu's Arteritis;   Urticarial Vasculitis
Intervention: Other: online questionnaire
4 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
5 Completed Reproductive Health in Men and Women With Vasculitis
Conditions: Giant Cell Arteritis;   Takayasu's Arteritis;   Polyarteritis Nodosa;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Behcet's Disease;   Kawasaki Disease;   Henoch-schoenlein Purpura;   Vasculitis, Central Nervous System;   Drug-induced Necrotizing Vasculitis
Intervention:
6 Active, not recruiting Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Condition: Vasculitis
Intervention: Drug: azathioprine
7 Completed MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
Conditions: Vasculitis;   Anti-Neutrophil Cytoplasmic Antibody
Intervention: Drug: mycophenolate mofetil
8 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
9 Completed Steroids and Methotrexate to Treat Systemic Vasculitis
Conditions: Inflammation;   Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: prednisone and methotrexate
10 Completed Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa
Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides;   Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;   Drug: Mycophenolate mofetil,methotrexate
11 Completed Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention:
12 Completed Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Conditions: Pneumococcal Infection;   ANCA-associated Vasculitis
Intervention:
13 Active, not recruiting Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
Condition: ANCA-associated Vasculitis
Interventions: Drug: CCX168 low dose plus standard of care;   Drug: CCX168 high dose plus standard of care;   Other: Placebo BID plus standard of care
14 Completed Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Mycophenolate Mofetil
15 Recruiting Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Conditions: Pneumococcal Infection;   ANCA-associated Vasculitis
Intervention:
16 Completed Correlation of Genetic Polymorphism and Livedo Vasculitis
Conditions: Livedo Vasculitis;   Livedoid Vasculitis;   Livedoid Vasculopathy;   Genetic Pleomorphism;   Leiden Mutation
Intervention:
17 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone
18 Withdrawn Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Retinoic acid;   Drug: Standard of care
19 Active, not recruiting The ANCA Vasculitis Questionnaire (AAV-PRO©)
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA);   Churg-Strauss Syndrome (CSS);   Granulomatosis With Polyangiitis (Wegener's) (GPA);   Wegener Granulomatosis (WG);   Microscopic Polyangiitis (MPA);   ANCA-Associated Vasculitis (AAV);   Vasculitis
Intervention: Other: Online questionnaire
20 Completed Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
Conditions: Systemic Lupus Erythematosus;   ANCA Associated Vasculitis
Intervention: Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years